Niwano Y, Kanai K, Hamaguchi H, Uchida K, Yamaguchi H
Pharmaceutical Research Institute, Nihon Nohyaku Co., Ltd.
Jpn J Antibiot. 1995 Jan;48(1):146-9.
In vitro studies with a new imidazole antifungal agent lanoconazole (LCZ) were carried out to confirm its fungicidal property of the anti-dermatophytic activity and unlikeliness of dermatophytes to acquire secondary resistance to this drug. Minimal cidal concentration (MCC) values of LCZ against 6 strains each of Trichophyton mentagrophytes and T. rubrum determined by the cellophane membrane method were in a range of 0.063 to 0.5 micrograms/ml, and much lower than those of bifonazole (16-32 micrograms/ml). The LCZ-sensitivity of both of the two testing strains of T. mentagrophytes did not decrease to less than one-fourth of the initial level during 15 subcultures on LCZ-containing agar. These results suggest that LCZ potently inhibits dermatophytes in a fungicidal manner and that secondary resistance to LCZ is not easily developed in the dermatophytes tested.
对新型咪唑类抗真菌药拉诺康唑(LCZ)进行了体外研究,以证实其抗皮肤癣菌活性的杀菌特性以及皮肤癣菌不太可能对该药物产生继发性耐药。采用玻璃纸膜法测定LCZ对须癣毛癣菌和红色毛癣菌各6个菌株的最低杀菌浓度(MCC)值在0.063至0.5微克/毫升范围内,远低于联苯苄唑的最低杀菌浓度(16 - 32微克/毫升)。在含LCZ的琼脂上进行15次传代培养期间,两种须癣毛癣菌测试菌株对LCZ的敏感性均未降至初始水平的四分之一以下。这些结果表明,LCZ以杀菌方式有效抑制皮肤癣菌,并且在测试的皮肤癣菌中不容易产生对LCZ的继发性耐药。